The Journal of Urology
Volume 177, Issue 1 , Pages 131-138 , January 2007

Recurrence Pattern and Proposed Surveillance Protocol Following Post-Chemotherapy Retroperitoneal Lymph Node Dissection

  • Philippe E. Spiess

      Affiliations

    • Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • Gordon A. Brown

      Affiliations

    • Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • Ping Liu

      Affiliations

    • Department of Biostatistics and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • Shi-Ming Tu

      Affiliations

    • Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • Nizar M. Tannir

      Affiliations

    • Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • James G. Evans

      Affiliations

    • Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • Ashish M. Kamat

      Affiliations

    • Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Financial interest and/or other relationship with Abbott, AstraZeneca and TetraLogic.
    • ,
  • Wassim Kassouf

      Affiliations

    • Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • Louis L. Pisters

      Affiliations

    • Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Corresponding Author InformationCorrespondence: Department of Urology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (telephone: 713-792-3250; FAX: 713-794-4824).
    • Financial interest and/or other relationship with Abbott Pharmaceuticals and Endocare.

Received 3 February 2006

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Study received Institutional Review Board approval.For another article on a related topic see page 395.Editor’s Note: This article is the second of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 410 and 411.

PII: S0022-5347(06)02168-9

doi: 10.1016/j.juro.2006.08.092

The Journal of Urology
Volume 177, Issue 1 , Pages 131-138 , January 2007

Article Tools

* Image Usage & Resolution